The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
FuchsC.S., MarshallJ., MitchellE.Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study. J Clin Oncol.2007; 25(30): 4779–4786.
2.
FuchsC.S., MarshallJ., BarruecoJ.Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol.2008; 26(4): 689–690.
3.
HurwitzH., FehrenbacherL., NovotnyW.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med.2004; 350(23): 2335–2342.
4.
SaltzL.B., ClarkeS., Díaz-RubioE.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol.2008; 26(12): 2013–2019.
5.
HochsterH.S., HartL.L., RamanathanR.K.Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol.2008; 26(21): 3523–3529.
6.
GiantonioB.J., CatalanoP.J., MeropolN.J.Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200J Clin Oncol.2007; 25(12): 1539–1544.
7.
KabbinavarF.F., HambletonJ., MassR.D.Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol.2005; 23(16): 3706–3712.
8.
KabbinavarF., HurwitzH.I., FehrenbacherL.Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol.2003; 21(1): 60–65.
9.
KabbinavarF.F., SchulzJ., McCleodM.Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol.2005; 23(16): 3697–3705.
10.
KopetzS., HoffP.M., MorrisJ.S.Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol.2010; 28(3): 453–459.
11.
LopezR., SalgadoM., ReboredoM.A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer. Br J Cancer.2010; 103(10): 1536–1541.
12.
SobreroA., AcklandS., ClarkeS.Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology.2009; 77(2): 113–119.
13.
GiantonioB.J., LevyD.E., O'DwyerP.J.A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol.2006; 17(9): 1399–1403.
KrisM.G., HeskethP.J., SomerfieldM.R.American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006;24: 2932–2947.
GelingO., EichlerH.G.Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
20.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetronantiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
21.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
22.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
23.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
24.
SoukopM.A.Dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety.2001; 24(10): 767–779.
27.
SmithT.J., KhatcheressianJ., LymanG.H.2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
30.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–402.
31.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
32.
BensonA.B., AjaniJ.A., CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
33.
MarounJ.A., AnthonyL.B., BlaisN.Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol.2007; 14(1): 13–20.
AronoffG.R., BennettW.M., BernsJ.S., BrierM.E., KasbekarN., MuellerB.A., PaskoD.A., SmoyerW.E.Drug Prescribing in Renal Failure.5th ed.Philadelphia: American College of Physicians; 2007.
37.
FloydJ., MirzaI., Sachs, PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33: 50–67.
38.
KingP.D.Perry MC. Hepatotoxicity of chemotherapy. Oncologist.2001; 6: 162–176.
